Introduction
The ability of cells to acquire specific and often unique fates as a function of their position in a developing field is a fundamental process in animal development. The genetic regulatory mechanisms that govern position-dependent cell-fate specification have been studied extensively in the developing vertebrate and Drosophila CNS. These studies reveal key parallels between the molecules that pattern the DV axis of the CNS in Drosophila and vertebrates. For example, the vnd homeodomain-containing gene and its vertebrate homolog Nkx2.2 regulate cell fate in the medial domains of the Drosophila and vertebrate neuroepithelia, respectively (Briscoe et al., 1999 , Chu et al., 1998 , McDonald et al., 1998 . ind, another homeodomain gene and its vertebrate homolog Gsh appear to control cell fate in the intermediate domain (Valerius et al., 1995 while the msh and Msx homeodomain-containing genes are expressed and control the development of cells in the lateral domain of the Drosophila and vertebrate neuroepithelium (Davidson, 1995 , Isshiki et al., 1997 .
The Drosophila CNS is an ideal model system in which to dissect the genetic and molecular mechanisms that pattern and regulate cell-fate specification in the CNS (reviewed in Skeath and Thor, 2003) . The Drosophila CNS develops from a set of neural stem cells, called neuroblasts (NBs) , that arise from the ventrolateral ectoderm and divide to produce the neurons and glia that populate the CNS. Within each hemisegment of the Drosophila CNS every NB acquires a unique fate based on its position and time of formation. A set of six genes collectively referred to here as the "columnar genes" patterns the CNS along the DV axis and functions to enable NBs that develop in different DV positions to acquire position-specific fates (reviewed in Skeath, 1999, Skeath and Thor, 2003) . The columnar genes include the Drosophila EGF receptor (Egfr), three homeodomain transcription factors -vnd, ind and msh -and Dichaete and Sox Neuro two high mobility group (HMG) domain transcription factors. These genes interact in a complex genetic hierarchy to partition the DV axis of the CNS into three discrete longitudinal columns: medial, intermediate and lateral.
vnd, ind and msh were the first genes identified that pattern the CNS along the DV axis. vnd, ind and msh are expressed in the medial, intermediate and lateral columns respectively. vnd and ind control NB formation and specification within their expression domains (Chu et al., 1998 , McDonald et al., 1998 while msh regulates the differentiation of lateral column NBs. Molecular epistasis tests indicate that vnd represses ind and that ind represses msh (McDonald et al., 1998 . In this genetic hierarchy the more ventrally expressed gene establishes via repression the ventral limit of the gene expressed immediately dorsal to it.
Recently the Dichaete and SoxN transcription factors have been shown to act in parallel to vnd and ind to pattern the DV axis of the CNS (Buescher et al., 2002 , Cremazy et al., 2000 , Overton et al., 2002 , Zhao and Skeath, 2002 . Dichaete is expressed in the medial and intermediate columns while SoxN is expressed uniformly throughout the CNS. Genetics studies indicate that Dichaete and SoxN act in a partially redundant manner to regulate NB formation and fate within each column of the CNS (Buescher et al., 2002 , Overton et al., 2002 .
Egfr stands atop the genetic regulatory hierarchy that patterns the CNS along the DV axis. spitz and vein each encode ligands that activate Egfr independently of one another , Rutledge et al., 1992 , Schnepp et al., 1996 , Schweitzer et al., 1995 . The Spitz precursor is expressed broadly (Rutledge et al., 1992) in its inactive form. rhomboid encodes a membranespanning protein (Bier et al., 1990 ) that appears to mediate Egfr signaling by helping to process Spitz from its inactive transmembrane form to its active secreted form . Localized transcription of rhomboid in the ventral domains of the neuroectoderm lead to localized Egfr activation (Bier et al., 1990 , Gabay et al., 1996 , Schnepp et al., 1996 in the medial and intermediate columns prior to NB formation (Skeath, 1998) where it positively regulates vnd, ind and Dichaete expression and represses msh expression (Gabay et al., 1996, Zhao and Skeath, 2002) . Egfr promotes the formation of intermediate column NBs by activating ind expression (Skeath, 1998, von Ohlen and Doe, 2000) and of late forming medial column NBs likely by maintaining vnd expression in the medial column (Zhao and Skeath, 2002) . The ability of Egfr to activate ind also accounts for Egfr's ability to restrict msh expression to the lateral column.
In addition to its role in NB formation, Egfr also helps specify the fate of early forming medial NBs. In the absence of Egfr function, medial NBs arise normally but acquire inappropriate fates about 50% of the time (Skeath, 1998) . This activity of Egfr appears independent of vnd and achaete/scute gene expression as expression of these genes in medial NBs is wild-type in Egfr mutant embryos. Of note, this mis-specification phenotype of medial NBs is essentially identical to that caused by the Fig. 1 Egfr* activates the expression of vnd and ind, but represses msh expression. High magnification ventral views of the neuroectoderm in wild-type (A-E) and Egfr* (F-J) embryos labeled for Vnd (A,B,F,G), Ind (C,D,H,I) and Msh (E,J) protein expression. In wild-type embryos, (A) vnd is expressed in the medial column of the neuroectoderm at stage 9 and (B) in the neuroectoderm and certain neuroblasts at stage 10. In Egfr* embryos, (F) ectopic vnd expression first appears in the lateral column during stage 9 (arrowhead) and (G) is expressed throughout the neuroectoderm by late stage 10, although some intermediate and lateral column neuroectoderm cells do not express vnd (asterisk). In wild-type embryos, ind is expressed in the intermediate column neuroectoderm during stage 9 (C) and neuroblasts during stage 10 (D). In Egfr* embryos, ind expression expands into the lateral column before stage 9 (H) but is restricted to only intermediate column neuroblasts by stage 10 (I). msh is expressed in the lateral column in wild-type embryos (E) but is greatly reduced in Egfr* embryos (J). Anterior, left; line, ventral midline. m, i, l (l'sc) in the place of achaete (ac) and scute (sc) within the medial NB MP2 (Parras et al., 1996, Skeath and Doe, 1996) . Although the genetic relationship between Egfr and the ac/sc genes remains unresolved, the near identity of the phenotypes suggests Egfr and the ac/sc genes either act in parallel or sequentially in the same pathway to specify medial column NBs.
The aforementioned work provides a solid framework of the genetic hierarchy through which the columnar genes pattern and regulate cell fate along the DV axis of the CNS. Despite this foundation, other studies hint at additional layers of complexity within this hierarchy. For example, the precise genetic relationship between Egfr and vnd as well as ind appears unclear. von Ohlen and Doe (von Ohlen and Doe, 2000) showed that ubiquitous activation of Egfr is sufficient to activate ind but not vnd in the lateral column. In contrast, Gabay et al. (Gabay et al., 1996) observed that ubiquitous Egfr activity is sufficient to activate vnd expression in the lateral column. These results suggest our understanding of the genetic control of DV patterning in the CNS is incomplete.
In this study, we combine ectopic activation of Egfr activity with loss of function genetics to dissect the genetic hierarchy of DV patterning in the CNS. Through this work we establish that the genetic requirements for the medial column fate are the presence of Egfr activity, vnd expression and the absence of ind expression while those for the intermediate column fate are the initial presence of Egfr activity, ind expression and the absence of vnd expression. We also find that ind can and does repress vnd expression in the developing CNS. Finally, we demonstrate that Egfr and the achaete-scute genes act in parallel to control the fate of individual medial NBs.
Results

Ubiquitous Egfr activity changes the dorsoventral subdivision of the neuroectoderm
To gain a more in depth understanding of Egfr-mediated regulation of vnd, ind and msh, we assayed the effect of ubiquitous Egfr activity on vnd, ind and msh expression in the neuroectoderm and on NB fate. We activated the Egfr signaling pathway throughout the early embryo by using maternal Gal4 driver lines and UAS-s-spi. We refer to these embryos as Egfr* embryos. Ubiquitous expression of the active diphosphorylatedform of MAP kinase, a marker of Egfr activity (Gabay et al., 1996) , confirmed ubiquitous activation of the Egfr pathway in these embryos (data not shown).
We observe that ubiquitous activation of Egfr expands the expression of vnd and ind into the lateral column and reduces that of msh in the lateral column (Fig. 1) . The vnd and ind expression profiles in the lateral column exhibit significant temporal and spatial differences. In Egfr* embryos, ind expression expands into the lateral column prior to stage 9 (Fig. 1H ), but is restricted to intermediate column NBs in a pattern that closely resembles wild-type by stage 10 (compare Figs. 1D, I ). In contrast, vnd expression comes on in the lateral column towards the end of stage 9 (Fig. 1F) . At this stage the intermediate column is devoid of vnd expression. However, by stage 10 we detect vnd expression throughout the neuroectoderm, although a few intermediate column cells still lack vnd expression (Fig. 1G, asterisk) . Thus, Egfr activity is sufficient to activate both vnd and ind in the lateral column although to different extents and at different times. The inability of ubiquitous Egfr activity to activate vnd or ind outside the CNS suggests the presence of factors, such as dpp, that actively suppress, or the absence of factors that are necessary for Egfr-mediated activation of, vnd and ind expression in this domain.
Egfr*-mediated activation of vnd and ind in the lateral column was unexpected in light of previous experiments that demonstrated that vnd represses ind (McDonald et al., 1998) and that ubiquitous Egfr activity leads to the expansion of ind, but not vnd, in the lateral column (von Ohlen and Doe, 2000) . Our double label immunofluorescence studies show that vnd and ind exhibit mutually exclusive expression patterns in the CNS of Egfr* embryos at all developmental stages (Fig. 2) . Thus, although vnd and ind are expressed in the same DV domains in these embryos, on a cell-by-cell basis their expression patterns remain mutually exclusive consistent with the known ability of vnd to repress ind.
Different columnar gene expression in the neuroectoderm leads to different neuroblast fates
The sequential expression of ind and vnd in the lateral column of Egfr* embryos prior to and during the first wave (SI) of NB formation led us to investigate the formation and fate of these NBs. We first assayed NB formation and observed a significant decrease in the formation of each lateral column SI NB, as NB 2-5, NB 3-5, NB 5-6 and NB 7-4 are present in 20.7%, 36.7%, 20.2% and 3.7% of hemisegments, respectively (n = 430 hemisegments scored for each NB). Next, we assayed the fate of these NBs at two different times -as they formed and either immediately prior to or just after their first division. At early stages many lateral column NBs display traits consistent with an intermediate column fate, while at later stages these NBs display medial column fates. For example, in wild-type embryos the medial and lateral column SI NBs of row 3 and 7 (MP2, 3-5, 7-1, 7-4) express Achaete (Ac, Fig. 3A ) while those of row 1 (1-1, 2-5) express Odd-skipped (Odd, Table 1 ). However, in Egfr* embryos, lateral NBs in rows 3 and 7 either do not express Achaete or express it at very low levels ( Fig. 3B ) while the lateral NB of row 1 does not express Odd (Table 1) . Thus, in Egfr embryos a significant fraction of lateral NBs that form fail to display traits indicative of lateral NBs but rather initially appear most similar to intermediate column NBs, consistent with the early expression of ind in the lateral column of Egfr* embryos. The NBs that do exhibit Ac and Odd expression likely acquire their normal lateral column NB identity because at that time vnd has not initiated expression in the lateral column. At later stages most lateral NBs express markers consistent with a medial fate. For example, by stage 11 MP2, the row 3 medial column NB can be uniquely identified by the expression of Odd, Fushi-tarazu (Ftz) and nuclear Prospero (Pros) protein and the first-born progeny of NB 4-2, the row 3 intermediate column NB, can be identified by Eve expression. Using these markers, we observe that more than 20% of hemisegments contain an ectopic MP2 located more laterally in row 3 (Fig. 3E , Table 1 ) relative to less than 2% for NB 4-2 (Table 1) . As we only observe a lateral column NB in 36.7% of hemisgements, this suggests that ~60% of all lateral column NBs in this position (Fig. 4B ) and uniform vnd expression in all neuroectodermal cells by mid stage 9 (Fig. 4D) . The earlier ectopic activation as well as uniform expression of vnd in the Egfr* ind -embryos indicate that ind represses vnd expression in the intermediate and lateral columns in Egfr* embryos.
Although ind has not been reported to regulate vnd expression, our demonstration that ind represses vnd under conditions of uniform Egfr activity led us to ask if ind normally helps establish the sharp lateral limit of vnd expression in wild-type embryos. In stage 9 embryos vnd is expressed in two-bilaterally symmetric columns of neuroectodermal cells that flank the ventral midline. These rows are two-three cells wide and exhibit a sharp lateral boundary (Fig. 4I) . In ind -embryos the two columns of vnd -positive cells are present however they display a jagged lateral boundary and their width varies from two-to-five cells (Fig. 4J) . The erratic and expanded lateral boundary of vnd expression reveals that ind helps establish the precise lateral boundary of vnd expression. Although this is the first demonstration of cross-repressive interactions between the genes that pattern the DV axis of the Drosophila CNS such interactions are a common theme in the DV patterning of the vertebrate CNS.
Egfr* ind -embryos exhibit a significant reduction of NB formation in intermediate and lateral columns (Table 1) ; this phenotype is similar to that observed for ind mutant embryos for the intermediate column. Consistent with the transformation of the entire CNS to the medial column, NBs in all three columns acquire the medial column fate. In fact, relative to Egfr* embryos, Egfr* ind -embryos exhibit a two-to-seventeen fold increase of lateral column NBs acquiring a medial fate (Table 1) , indicating a much stronger medial transformation of the neruoectoderm. For example, NBs in all three columns express Ac in row 3 and 7 (Fig. 3C ) and various molecular markers reveal a triplication of the medial column NBs 1-1, MP2 and 7-1 (Fig. 3F , Table 1 ). NBs of intermediate or lateral fates are rarely if ever observed (data not shown). The significant reduction in NB formation in the intermediate and lateral columns likely accounts for the low frequency at which we observe triplication of medial NBs within one AP row (Table 1) . Together these results establish the genetic requirements sufficient for medial column fate in the CNS as ubiquitous Egfr activity in the absence of ind function.
Egfr can promote ind expression throughout the neuroectoderm in the absence of vnd function
As vnd is known to repress ind, the transient expression of ind in the lateral column of Egfr* embryos may arise as a result of vnd-mediated repression. To test this we assayed ind expression in vnd -; Egfr* embryos and found these embryos express ind throughout the entire neuroectoderm between stages 7 and 9 (Fig. 4F) . Thus, loss of vnd function together with ubiquitous activation of Egfr appears sufficient to re-specify the entire neuroectoderm towards the intermediate column fate. Subsequent to stage 9 in vnd -; Egfr* embryos, ind expression remains in all NBs throughout the CNS but disappears from the neuroectoderm (Fig. 4H) . Therefore, additional timing mechanisms must be involved in down-regulation of ind expression as despite the presence of uniform Egfr activity ind expression is still extinguished in the neuroectoderm by stage 10. Uniform ind expression throughout the neuroectoderm in the vnd -; Egfr* embryos suggests that the entire CNS acquires intermediate fate. Consistent with this, we observe triplication of GMC 4-2, the first progeny of intermediate column NB 4-2 in row 3 (Fig. 3I) , suggesting that all row 3 NBs acquire intermediate column NB 4-2 fate. In addition, we have not observed expression of markers specific for NBs with medial or lateral fates (data not shown). These data suggest a complete transformation of the entire CNS to the intermediate fate and establish that the presence of ubiquitous Egfr activity and the absence of vnd are sufficient to promote the intermediate fate throughout the entire CNS.
Egfr activity and the achaete/scute genes converge to specify medial column neuroblast fate
Previous studies indicate that Egfr activity and the activity of achaete/scute genes help specify the fate of medial column NBs (Parras et al., 1996 , Skeath, 1998 , Skeath and Doe, 1996 , Udolph et al., 1998 . The roles of the Egfr and ac/sc genes in medial column NB specification have been best studied for MP2. MP2 arises from a cluster of ac and sc expressing cells and is unique in that it is the only NB that localizes Pros protein to the nucleus (all other NBs localize Pros to the cell cortex) and also expresses Odd and Ftz. Loss of Egfr activity has little to no effect on NB formation in the MP2 position but only half of these NBs display the defining characteristics of MP2. All other NBs localize Pros to the cell cortex and fail to express Odd and Ftz -traits consistent with a NB fate distinct from MP2 (Parras et al., 1996 , Skeath, 1998 , Skeath and Doe, 1996 , Udolph et al., 1998 . Replacing ac and sc gene expression with that of l'sc leads to an essentially identical phenotype with respect to NB formation and specification in the MP2 position (Skeath and Doe, 1996; Parras et al., 1996) .
The similarity of the phenotypes suggests the Egfr and ac/sc genes may act in the same pathway, or alternatively in parallel to control MP2 fate and more general medial column NB fate. To distinguish these models we created Egfr mutant embryos that express l'sc in the place of ac and sc in MP2 (see Materials and Methods) . Consistent with the idea that Egfr and the ac/sc genes act in parallel we observed that a NB almost always forms in the MP2 position (92.5%; n=482) in this background but that this NB almost never displays traits indicative of MP2 (Fig. 5) . For example, NBs in this position rarely express Odd (3%, n=506), Ftz (1.6%, n=494) or nuclear Pros (0.8%, n=370) (Fig. 5) . Rather, these NBs localize Pros to the cell cortex (arrow, Fig. 5H ) or to the nucleus of a GMC (arrowhead, Fig. 5H ) consistent with acquiring traits characteristic of other neuroblasts. As a control, we verified that misexpression of l'sc in the place of ac and sc in the MP2 position essentially always promotes the formation of a NB in the MP2 position but that this NB acquires the MP2 fate only approximately half of the time (Skeath and Doe, 1996 ; data not shown). Taken together these results indicate that the Egfr signaling pathway and the proneural ac/sc genes act in parallel to control MP2 fate.
Discussion
The genetic control of dorsoventral patterning and cell fate in the Drosophila CNS The Dorsal gradient initiates patterning of the CNS via the transcriptional regulation of the expression vnd, rhomboid and zen (Stathopoulos and Levine, 2002) . Dorsal-mediated activation of rhomboid, the rate-limiting factor in Egfr-signaling and vnd establishes the initial expression domains of two of the earliest positive activators of CNS patterning along the DV axis. Similarly, Dorsal-mediated repression in the ventral and ventrolateral ectoderm limits the expression of zen and decapentaplegic (dpp) to the dorsal ectoderm (Rusch and Levine, G 1996) . Dpp functions as a morphogen and defines via a repressive mechanism the lateral limit of the developing CNS .
Within the CNS, vnd and rhomboid exhibit differential sensitivity to the dorsal gradient with vnd being activated solely within the medial column and rhomboid in both the intermediate and medial columns (Bier et al., 1990, Mellerick and Nirenberg, 1995) . As rhomboid is the limiting factor in Egfr signaling, its presence activates Egfr-signaling activity in the medial and intermediate columns , Urban et al., 2001 . In wild-type embryos, Egfr activity maintains vnd expression in the medial column and is necessary to promote ind expression in the intermediate column (Gabay et al., 1996, von Ohlen and Doe, 2000) . The ability of vnd to repress ind expression explains the restriction of ind expression to the intermediate column. vnd expression persists throughout most of the medial column until the end of embryogenesis; in contrast, ind expression is extinguished in the intermediate column neuroectoderm by stage 10 after the first two (of five) waves of NB segregation.
Our work adds a new regulatory relationship into the genetic regulation of CNS patterning as we find that ind helps establish the lateral limit of vnd expression. ind could perform this function via the direct repression of vnd, a possibility supported by our gain-of-function and loss-of-function experiments. If this model is correct, the mutual repression of vnd and ind would bear striking similarity to the reciprocal repressive interactions observed for the class I and class II homeodomain proteins that pattern the DV axis of the vertebrate CNS (Briscoe et al., 2000) . In this context, it is important to note that the vertebrate ortholog of vnd, Nkx2.2., is a class II protein that plays a key role in patterning some of the ventral-most regions of the vertebrate CNS. Alternatively or additionally, vnd and ind could establish their mutual sharp boundary indirectly via the regulation of other factors. For example, differential regulation of homophilic cell-adhesion molecules could account for the observed phenotype. Differential expression of cell-adhesion molecules on medial versus intermediate column cells would cause these cells to associate preferentially with cells from the same column and result in a sharp boundary between the two cell populations that minimized interaction. Loss of such differences would reduce the requirement to minimize interactions and likely result in a jagged boundary. Additional work is necessary to identify the precise mechanism through which ind helps establish the lateral limit of vnd expression. Previous work has shown that misexpression of ind along the anterior-posterior axis using the Krüppel enhancer failed to repress vnd expression in the medial column (Cowden and Levine, 2003) . However, this is not contradictory to our finding. Our work suggests that ind can repress vnd in the intermediate and lateral columns but not in the medial columns. It is likely that some factors that are present in the intermediate and lateral columns but are absent in the medial column help ind to repress vnd.
In addition, our work, for the first time, demonstrates that Egfr and vnd are sufficient to confer medial fate and that Egfr and ind are sufficient to confer intermediate fate. Although lossof-function studies have shown that both Egfr and vnd are necessary for NBs to acquire medial fate, it is not clear whether Egfr functions solely through vnd. McDonald et al. (McDonald et al., 1998) have shown that ectopic vnd expression results in partial transformation of lateral column into medial column. Our work shows that ectopic Egfr activity can induce the expression of vnd and together Egfr and vnd fully transform the lateral column into the medial column. Therefore, Egfr likely plays additional roles in determining medial cell fate other than maintaining vnd expression in the neuroectoderm. However, it remains unclear whether Egfr contributes to the intermediate column NB fate determination other than through its regulation of ind and whether ind by itself is sufficient to confer intermediate fate. Further studies are necessary to dissect the regulatory mechanisms that control intermediate column NB fate specification. In addition, while our work did not address the roles of Dichaete and Sox-Neuro, we have reported that ubiquitous EGFR signaling activates Dichaete expression throughout the neuroectoderm (Zhao and Skeath, 2002) . Because Dichaete and SoxNeuro cooperates with vnd in the mediate column and ind in the intermediate column in NB fate specification (Buescher et al., 2002 , Overton et al., 2002 , Zhao and Skeath, 2002 , they are likely to act as co-factors with Vnd and Ind in Egfr* embryos to specify NB fate in the lateral column.
Temporal regulation of gene expression during CNS patterning
Our experiments also underline the importance of temporal regulation of gene expression during CNS patterning. This is most notable with respect to the dynamic regulation of ind and vnd expression by Egfr signaling. Figure  3 ), we find that ind expression turns over at its normal time even in the presence of ubiquitous and prolonged Egfr activity in the CNS (Fig. 3) . Thus, even though Egfr activity is necessary and sufficient for the activation of ind, once activated ind expression in the CNS appears to become independent of Egfr activity and other factors must regulate its temporally precise downregulation in the CNS.
Similarly, vnd also exhibits differential sensitivity to Egfr activity as a function of time. In contrast to ind, Egfr activity is not necessary to activate vnd expression in the medial column, however, Egfr activity is required later to maintain vnd expression in this domain. Thus, vnd and ind exhibit opposite responses to the Egfr signaling -ind is activated but not maintained by Egfr activity while vnd is maintained but not activated by this pathway. It is interesting to note that vnd becomes competent to respond to Egfr signaling about the time ind loses its ability to respond to this signal. While the differential competency of the vnd and ind promoters to Egfr signaling is essential for proper DV patterning of the CNS, the molecular bases of these differences remain unknown. Some of the specificity
likely resides within the promoters or regulatory regions of the genes themselves. However, since both promoters are Egfrresponsive albeit at different times additional levels of regulation appear necessary to explain the complexity in regulation. Alteration to higher order chromatin structure is known to play a key role in controlling the competency of different promoters to respond to specific signals (McKinsey et al., 2002) and is a clear candidate to help mediate the differential responses of ind and vnd to Egfr-activity. However, how chromatin structure affects the ability of ind and/or vnd to respond to Egfr-activity remains unexplored. Future work that addresses the influence of modulation of chromatin structure on the ability of these and other genes to respond differentially to the same inputs should shed light on basic principles of gene regulation during development.
Convergent control of neuroblast specification
Our genetic studies indicate that the activities of Egfr and the ac/sc genes converge to specify the fate of MP2 and possibly other NBs. Additional work on genes that regulate NB fate suggests that distinct convergent signals may play a general role in NB specification. For example, the transcription factor huckebein is expressed in NB 4-2 and its associated proneural cluster and helps promote the fate of some of the neurons that develop in the 4-2 lineage (Chu-LaGraff et al., 1995) . However, in the absence of huckebein function, the 4-2 lineage retains many of its wild-type characteristics (Chu-LaGraff et al., 1995) . Thus additional intrinsic and extrinsic cues likely converge with huckebein to control the fate of NB4-2 and enable it to elaborate its proper cell lineage. Similar, albeit less detailed observations, have been made for runt and msh (Buescher and Chia, 1997 , Dormand and Brand, 1998 , Isshiki et al., 1997 . These genes are expressed in specific NBs and the cell clusters from which they delaminate. Each gene appears to regulate only a subset of the distinguishing characteristics of the neuronal lineages that arise from their respective NBs yet none of them appears deterministic for a specific NB fate. Thus, we speculate that convergent regulation of NB fate by multiple intrinsic and extrinsic factors is a general theme in CNS development and that classical double and triple mutant analyses will be essential to reveal convergent pathways involved in NB as well as neuronal specification.
Materials and Methods
Fly strains and genetics
Wild-type patterns of gene expression were examined in Oregon R embryos. Ectopic activation of the Egfr signaling pathway was accomplished by using UAS/Gal4 system (Brand and Dormand, 1995) . The following fly lines were used: In(1)y 3PL sc 8R ; scabrous-Gal4 (sca-Gal4) and UAS-l'sc. tub-Gal4 fly is kindly provided by D. St Johnston (Jazwinska et al., 1999) . This fly line carries a transgene in which the DNA binding domain of GAL4 fused to the VP16 transcriptional activation domain expressed from the α4-tubulin promoter. UAS-s-spi on the second chromosome is kindly provided by A. Michelson (Schweitzer et al., 1995) . We mobilized UAS-s-spi to the third chromosome by providing with transposes. When we ubiquitously express it with tub-Gal4 driver, we got identical phenotype in both CNS patterning and cell fate specification as UAS-s-spi in the second chromosome. All our analyses were performed using UAS-s-spi on the third chromosome because it is healthier. Mutant lines used were: Egfr: flb 1k35 and flb 1F26 (Clifford and Schupbach, 1994) ; ind RR108 ; vnd ∆38 (Chu et al., 1998) ; To ectopically express s-spi in ind mutant background, virgin females from tub-GAL4/Cyo-ftz lacZ; ind RR108 /+ were crossed to ind RR108 -UAS-sspi/TM3-ftz lacZ at 25ºC. Embryos resulting from the cross were fixed and stained for one of the markers and β-galactosidase. We identified embryos of the appropriate genotype by the lack of β-galactosidase expression as well as by expected phenotypic ratios and the specific observed phenotypes.
To express ectopically s-spi in vnd mutant background, virgin females from vnd ∆38 /FM7-ftz lacZ; tub-GAL4 were crossed to UAS-s-spi male at 25ºC. We fixed, stained and scored embryos resulting from the cross for each markers and β-galactosidase and identified embryos of the appropriate genotype as noted in the prior paragraph.
For MP2 specification experiments, two fly lines were used: In(1)y 3PL sc 8R ; flb IF26 sca-Gal4 / CyO-ftz-lacZ carries a deletion of ac/sc genes and Egfr temperature sensitive mutation (restriction temperature 28ºC). The sca-Gal4 insertion activates genes placed after the Gal4 upstream activating sequence (UAS) throughout the neuroectoderm at stage 8-9. In(1)y 3PL sc 8R ; flb 1K35 UAS -l'sc / CyO-ftz-lacZ carries a deletion of ac/sc genes and Egfr null mutation. In(1)y 3PL sc 8R deletes the ac gene and the enhancer sequences of sc (the coding sequence of sc is still present) which results in lack of ac and sc expression in MP2. Virgin females from In(1)y 3PL sc 8R ; flb IF26 sca-Gal4 / CyO-ftz-lacZ were crossed to In(1)y 3PL sc 8R ; flb 1K35 UAS-l'sc / CyO-ftz-lacZ males or vise versa at 29ºC. Embryos resulting from the cross were fixed and stained for one of the markers and β-galactosidase. Embryos that lacked β-galactosidase expression in the ftz pattern were scored for the various markers in the MP2 position. These embryos have a genotype of In (1) 8R ; scaGal4 / UAS-l'sc. All embryos were raised at 29ºC.
Immunohistochemistry of whole mount embryos
Single-and double-label immunohistochemistry analyses were performed as described elsewhere . For the active MAP kinase antibody, we used biotinyl tyramide (NEN Life Science Products) to amplify the signal following the manufacturer's protocol. We used the following antibodies at the indicated dilutions: mouse anti-Achaete (1:3) ; rabbit anti-Vnd (1:10) (McDonald et al., 1998) ; rat anti-Ind (1:250) ; rabbit anti-Msh (1:600) (Isshiki et al., 1997) ; rabbit anti-Eve (1:2000) (Frasch et al., 1986) ; mouse antiEngrailed 4D9 (1:5) (Patel et al., 1989) ; mouse anti-βgal (1:2000; Promega); mouse anti-Pros MR1A (1:3) (Spana and Doe, 1995) ; mouse anti-Ftz (Kellerman et al., 1990) ; rabbit anti-Odd (1:2000; kindly provided by Ellen Ward); GP anti-Hb (1:400; kindly provided by David Kosman) and mouse anti-Active MAP kinase (1:2000; Sigma) (Gabay et al., 1996) .
